KeyNeurotek Pharmaceuticals AG
About KeyNeurotek
KeyNeurotek Pharmaceuticals was spun out of the renowned Magdeburg research environment, one of the leading neuroscience centers in Europe, in 2000. Based on an internationally leading technology platform (TELOMICSTM), the company focuses on the development and commercialization of a mature and diversified research and development pipeline for the treatment of traumatic brain injury, stroke, Alzheimer's disease and urinary incontinence.
KeyNeurotek Pharmaceuticals has a number of product candidates in preclinical and advanced clinical development stages. In addition, the company has long-standing collaborations with the pharmaceutical industry (e.g. Bayer Schering, Schwarz Pharma/UCB, Grünenthal) and renowned research institutions (e.g. Leibniz Institute for Neurobiology, University of Leipzig, Max Planck Society, Fraunhofer Society).
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Industry : Pharma
